Previous 10 | Next 10 |
Pfizer (PFE) has emerged as one of the winners in the race for an effective COVID-19 vaccine. It was the first company to receive commercial authorization from multiple regulatory bodies in the U.S. and throughout the world and began rolling out its vaccine in the U.S. last week. However, the...
BeiGene's (BGNE) BLINCYTO (blinatumomab) for injection for the treatment of adult patients with relapsed or refractory (R/R) B-cell precursor acute lymphoblastic leukemia ((ALL)) has been approved in China.The BLA had been submitted by Amgen (AMGN) and has received priority review in the...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the China National Medical Products Administration (NMPA) has approved BLINCYTO ® (blinatumomab) fo...
In previously treated patients with B-cell malignancies who were intolerant to other BTK inhibitors, adverse events were unlikely to recur on zanubrutinib with responses maintained or improved compared to prior treatment Zanubrutinib demonstrated deep and durable responses in ...
Zanubrutinib was shown to be highly active in patients with relapsed/refractory marginal zone lymphoma in initial results from the Phase 2 MAGNOLIA trial Zanubrutinib demonstrated an overall response rate of nearly 95 percent and a sustained progression-free survival in treatm...
BeiGene (BGNE) has priced 1,511,546 American Depositary Shares, each representing 13 of its ordinary shares, par value $0.0001 per share, by fund partnerships affiliated with Baker Bros. Advisors LP at $225/ADS.Underwriters' over-allotment is an additional 151,154 ADSs.Offering is expected to...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the pricing of an underwritten public offering of 1,511,546 American Depositary Shares (“ADSs”), ea...
BeiGene (BGNE) has commenced an underwritten public offering of 1.5M ADSs, each representing 13 of ordinary shares, by Baker Bros. Advisors. Underwriter have an option to purchase up to an additional 151k ADSs. The company will not receive any of the proceeds from the sale of the sh...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the commencement of an underwritten public offering of 1,511,546 American Depositary Shares (“ADSs”...
BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced that the Company will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference. Presentations w...
News, Short Squeeze, Breakout and More Instantly...
BeiGene Ltd. Company Name:
BGNE Stock Symbol:
NASDAQ Market:
Study evaluating BRUKINSA ® in combination with venetoclax in high-risk, treatment-naïve CLL/SLL patients to be shared as oral presentation BCL2 inhibitor sonrotoclax subject of multiple presentations highlighting promising safety and efficacy as monotherapy and in c...
Total revenues of $752 million in the first quarter, including product revenue of $747 million, an 82% increase from the prior-year period BRUKINSA revenue of $489 million, driven by growth in the U.S. and Europe of 153% and 243%, respectively, from the prior-year period; with recent fift...